Insider Selling: Francis Reynolds Sells 24,000 Shares of Invivo Therapeutics Holdings Corp Stock (NVIV)
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) major shareholder Francis Reynolds unloaded 24,000 shares of the company’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $1.35, for a total value of $32,400.00. Following the sale, the insider now directly owns 10,751,920 shares of the company’s stock, valued at approximately $14,515,092. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
A number of analysts have recently weighed in on NVIV shares. Analysts at Zacks reiterated a “neutral” rating on shares of Invivo Therapeutics Holdings Corp in a research note to investors on Tuesday, August 27th. They now have a $2.00 price target on the stock. Analysts at Aegis raised their price target on shares of Invivo Therapeutics Holdings Corp from $6.00 to $7.00 in a research note to investors on Friday, August 23rd. They now have a “buy” rating on the stock.
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) traded down 3.76% on Monday, hitting $1.28. 219,685 shares of the company’s stock traded hands. Invivo Therapeutics Holdings Corp has a 52-week low of $1.25 and a 52-week high of $6.20. The stock has a 50-day moving average of $3.31 and a 200-day moving average of $3.32. The company’s market cap is $100.6 million.
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.